<DOC>
	<DOC>NCT02364635</DOC>
	<brief_summary>PRC 4016 (Icosabutate) - A Phase I, Single-Blind, Placebo Controlled, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects Objective: - To assess the safety and tolerability of single ascending oral doses of icosabutate in healthy subjects - To evaluate the pharmacokinetic (PK) parameters of icosabutate in healthy subjects</brief_summary>
	<brief_title>Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>males of females any ethnic origin Age 1855 years BMI 18.0 33.0 kg/m2 generally in good health signed informed consent males or females not willing to use appropriate contraception recent blood donation recent blood received high consumption of alcohol high consumption of tobacco subjects who have engaged in heavy exercise last two weeks prescribed systemic or topical medication taken recently, or supplements/remedies interfering with study procedures or safety other medication know to alter drug absorption or elimination abnormal heart rate or blood pressure or 12lead ECG significant history of drug allergy, or hypersensitivity to treatment ingredients ocular disorder requiring topical ocular therapy, or recent allergic eye disease other significant medical history or physical findings</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Phase I pharmacokinetics and safety study</keyword>
</DOC>